I. Requirements for Prior Authorization of Stimulants and Related Agents

A. Prescriptions That Require Prior Authorization

Prescriptions for Stimulants andRelated Agents that meet the following conditions must be prior authorized.

1. A prescription for a non-preferred Stimulant and Related Agent. See Preferred Drug List (PDL) for the list of preferred Stimulants and Related Agents at: www.providersynergies.com/services/documents/PAM_PDL.pdf

2. A prescription for a preferred Stimulant and Related Agent with a prescribed quantity that exceeds the quantity limit. See Quantity Limits for the list of drugs with quantity limits at: http://www.dpw.state.pa.us/provider/doingbusinesswithdpw/pharmacieservices/quantitylimitslist/index.htm

3. A prescription for a preferred or a non-preferred Stimulant and Related Agent for a recipient under 4 years of age

4. A prescription for a Stimulant and Related Agent when there is a record of a recent paid claim for another drug within the same therapeutic class of drugs in the Department’s Point-of-Sale On-Line Claims Adjudication System (therapeutic duplication). EXCEPTION: Intuniv, Nuvigil and Provigil

5. A prescription for a preferred or non-preferred Stimulant and Related Agent for a recipient 18 years of age or older. EXCEPTION: Provigil and Nuvigil

GRANDFATHER PROVISION – The Department will grandfather prescriptions for non-preferred Stimulants and Related Agents within quantity limits when the PROMISe Point-Of-Sale On-Line Claims Adjudication System verifies that the recipient has a record of a paid claim for a non-preferred Stimulant and Related Agent within the past 90 days from the date of service of the new claim. If the recipient has a record of a paid claim for a non-preferred Stimulant and Related Agent, a prescription or a refill for the same Stimulant and Related Agent within the quantity limits will be automatically approved.

Grandfathering does not apply to prescriptions for either a preferred or non-preferred Stimulant and Related Agent when prescribed for a recipient under 4 years of age or 18 years of age or older, or that are considered to be duplicate therapy.

October 17, 2011
(Replacing November 15, 2010)
B. Review of Documentation for Medical Necessity

In evaluating a request for prior authorization of a prescription for a non-preferred Stimulant and Related Agent, the determination of whether the requested prescription is medically necessary will take into account the following:

1. For Provigil – Whether the recipient has a diagnosis of:

   a. Narcolepsy documented by:

      i. A multi-latency sleep test

      OR

      ii. A clinical interview if the prescriber is an American Board of Medical Specialties (ABMS) certified psychiatrist/sleep specialist

      OR

   b. Obstructive sleep apnea/hypopnea syndrome (OSAHS) documented by a Respiratory Disturbance of >5

      AND

      Therapeutic failure of Continuous Positive Airway Pressure (CPAP) to resolve excessive daytime sleepiness (documented by either Epworth greater than 10 or Multiple Sleep Latency Test [MSLT] less than 6)

      OR

   c. Shift work sleep disorder (SWSD) as documented by:

      i. Recipient’s recurring work schedule for one (1) month or longer

      OR

      ii. Shift work which results in sleepiness on the job or insomnia at home which interferes with daily living

      OR
d. Multiple sclerosis and is receiving treatment for fatigue associated with multiple sclerosis

2. For Intuniv, whether the recipient has a documented history of therapeutic failure of Guanfacine

3. For all other non-preferred Stimulants and Related Agents, whether the recipient has a history of therapeutic failure of the preferred Stimulants and Related Agents.

4. For children under 4 years of age - Whether the MA recipient
   
a. Has a diagnosis of:
      i. Attention Deficit Hyperactivity Disorder (ADHD), OR
      ii. Attention Deficit Disorder (ADD), OR
      iii. Brain injury, OR
      iv. Autism
   
   AND

b. Is being prescribed the medication by an appropriate specialist or in consultation with a:
      i. Pediatric Neurologist, OR
      ii. Child and Adolescent Psychiatrist. OR
      iii. Child Development Pediatrician

   AND

   c. Has chart documented evidence of a comprehensive evaluation by the prescriber or in conjunction with a specialist listed above

5. For therapeutic duplication, whether:
   
a. The recipient is being titrated to, or tapered from, a drug in the same class
   
   OR
   
b. Supporting peer reviewed literature or national treatment guidelines corroborate concomitant use of the medications being requested

6. For a preferred or non-preferred Stimulant and Related Agent for recipients 18 years of age and older:
a. For a Stimulant and Related Agent, whether the recipient has a diagnosis of Attention Deficit Hyperactivity Disorder (ADHD) as documented by a history consistent with the most current Diagnostic and Statistical Manual of Mental Disorders (DSM) criteria

OR

b. For a Stimulant Agent, whether the recipient has a diagnosis of narcolepsy as confirmed by:

i. A sleep study followed by a multiple sleep latency test

AND

ii. A history consistent with narcolepsy

AND

c. For a Stimulant Agent for a recipient with a history of ADHD or narcolepsy and co-morbid substance dependency, abuse or diversion, whether the recipient:

i. Is enrolled and actively participating in a substance dependency treatment program

AND

ii. Demonstrates compliance with the substance dependency treatment program as documented by a recent urine drug screen that tests negative for benzodiazepines, opiates and illicit drugs

OR

iii. Has a documented history of recovery and a recent negative urine drug screen for benzodiazepines, opiates and illicit drugs
OR

7. Whether the recipient does not meet the clinical review guidelines listed above, but, in the professional judgment of the physician reviewer, the services are medically necessary to meet the medical needs of the recipient.

C. Automated Prior Authorization Approvals

Prior authorization of a prescription for a non-preferred Stimulant and Related Agent in a quantity that does not exceed the quantity limit will be automatically approved when the PROMISe Point-of-Sale On-Line Claims Adjudication System verifies a record of paid claim(s) within 180 days prior to the date of service that documents that the guidelines to determine medical necessity listed in Section B. have been met.

Automated prior authorization approvals do not apply to the following:
1. A prescription for a preferred or non-preferred Stimulant and Related Agent with a prescribed quantity that exceeds the quantity limit
2. A prescription for a preferred or non-preferred Stimulant and Related Agent for a recipient under 4 years of age
3. Therapeutic duplication
4. A prescription for a preferred or non-preferred Stimulant and Related Agent for a recipient 18 years of age or older

D. Clinical Review Process

Prior authorization personnel will review the request for prior authorization and apply the clinical guidelines in Section B. above, to assess the medical necessity of the request for a prescription for a Stimulant and Related Agent. If the guidelines in Section B are met, the reviewer will prior authorize the prescription. If the guidelines are not met, the prior authorization request will be referred to a physician reviewer for a medical necessity determination. Such a request for prior authorization will be approved when, in the professional judgment of the physician reviewer, the services are medically necessary to meet the medical needs of the recipient.

All requests for prior authorization of a prescription for a Stimulant and Related Agent for a MA recipient under 4 years of age will be automatically forwarded to a physician reviewer (a psychiatrist) for a medical necessity determination. The physician reviewer (a psychiatrist) will consider the guidelines in Section B. above and will approve the request when, in the professional judgment of the physician reviewer (a
psychiatrist), the services are medically necessary to meet the medical needs of the recipient.

References:
12. Fact Sheet: Office of the National Drug Control Policy, Prescription Drugs: Weighing the Benefits and the Risks, December 2010